3.15
+1.61%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About C4 Therapeutics
From its filings with the US Securities and Exchange Commission
C4 Therapeutics is based in Watertown, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CCCC. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $35.9m and a net loss of $105.0m. At that date it held total assets of $359.1m and shareholders' equity of $256.6m.
We are a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines that transform patients’ lives. Leveraging our proprietary TORPEDO platform, we efficiently design and optimize small molecule protein degraders that are highly active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Our strategy is to develop degraders that modulate clinically validated disease pathways with best-in-class or first-in-class potential to address significant unmet patient needs. To date, our degraders have demonstrated oral bioavailability and catalytic activity, and we have also leveraged our capability to design compounds that are brain penetrant.
Our clinical pipeline has two oncology degraders, cemsidomide, an IKZF1 and IKZF3 degrader, for multiple myeloma, or MM, and CFT8919, an EGFR L858R degrader for non-small-cell lung cancer, or NSCLC. Our discovery strategy is focused on selecting targets where we believe TPD offers a compelling mechanistic rationale and first-in-class potential in inflammation, neuroinflammation and neurodegeneration diseases. Our solely-owned pipeline is reflected below.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Oct 2020
- Employees
- 104
- Website
- c4thera.com ↗
- Head office
- 490 ARSENAL WAY, WATERTOWN, MA, 02472
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Ronald CooperIndependent Chairman of the Board$346,199
- Mr. Andrew HirschPresident, Chief Executive Officer, Director, since 2020$5.2m
- Ms. Kendra AdamsChief Financial Officer, Treasurer$2.2m
- Ms. Kelly SchickChief People Officer
- Dr. Paige MahaneyChief Scientific Officer
- Dr. Scott BoyleChief Business Officer$3.9m
- Mr. Leonard ReynoChief Medical Officer$2.3m
- Ms. Jolie SiegelChief Legal Officer, Corporate Secretary$3.4m
- Dr. Kenneth AndersonIndependent Director, Co-Founder$176,625
- Dr. Laura BessenIndependent Director$180,625
- Dr. Stephen FawellIndependent Director$433,325
- Dr. Donna GroganIndependent Director$186,625
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 73
- Environment
- 78
- Social
- 81
- Governance
- 60
- Women in the workforce
- 57%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- C4 Therapeutics Inc has several strengths that contribute to its success in the market. One of its key strengths is its innovative approach to developing targeted protein degradation therapeutics. This unique strategy sets the company apart from its competitors and provides a competitive advantage in the industry. Additionally, C4 Therapeutics has a strong and experienced management team that brings expertise in drug discovery and development.
Weaknesses
- Despite its strengths, C4 Therapeutics Inc also faces certain weaknesses that need to be addressed. One weakness is the company's limited product pipeline. While its targeted protein degradation platform shows promise, the absence of a diversified portfolio puts the company at risk of relying heavily on a single product or technology. Furthermore, C4 Therapeutics faces challenges in scaling up its manufacturing capabilities to meet potential market demand.
Opportunities
- The market presents several opportunities for C4 Therapeutics Inc to capitalize on. Firstly, the growing demand for novel therapeutics and targeted drug delivery systems creates a favorable environment for the company's innovative approach. Additionally, C4 Therapeutics can explore strategic partnerships and collaborations with pharmaceutical companies to enhance its product development capabilities and accelerate the commercialization of its therapies. Furthermore, expanding into new geographic markets can also open up additional revenue streams for the company.
Threats
- C4 Therapeutics Inc faces certain threats that could impact its business operations. One major threat is the intense competition within the biopharmaceutical industry. The presence of established players with extensive resources and expertise poses challenges for a relatively small company like C4 Therapeutics. Moreover, regulatory and compliance requirements can pose obstacles to the successful development and commercialization of its products. Additionally, market volatility and economic uncertainties can impact the funding and investment landscape for the company.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.